Abstract
Controlled-release morphine sulfate tablet (MS-Contin: MS-C) has been reported to have the same analgesic effect on a twice-a-day regimen as aqueous morphine every 4hr.In this study, the pharmacokinetics of morphine and morphine-6-glucuronide (M-6-G) in cancer patients at steady state following oral administrations of three MS-C 10mg tablets every 12hr were compared with those following oral administrations of aqueous morphine (10mg) every 4hr.Elimination half-lives of morphine and M-6-G after administration of MS-C were found to be 2.58±0.85hr and 4.66±1.11hr, respectively, which were comparable to those after administration of aqueous morphine. On the other hand, absorption rate of morphine from MS-C was one-fourth of that obtained from the aqueous solution and the peak concentration from MS-C was less than three times that from the aqueous morphine and was observed about 3hr later compared with that from aqueous morphine solution. These results show that MS-C has sustained-release characteristics . The simulated curves of morphine and M-6-G plasma concentrations after MS-C administration were shown to be comparable to those after aqueous morphine administration. Moreover, in the two patients who received MS-C and aqueous morphine, the observed plasma concentration profiles were the same as the simulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
